Neurogene (NGNE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Voting matters and shareholder proposals
Election of Class III Directors for terms expiring in 2029, with nominees Robert Baffi, Ph.D. and Rohan Palekar recommended for election.
Advisory (non-binding) vote to approve the compensation of named executive officers.
Advisory (non-binding) vote to ratify Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
Advisory vote on the frequency of future say-on-pay votes, with a recommendation for every one year.
Proxies are authorized to vote on other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends the election of two Class III Directors for five-year terms expiring in 2029.
Executive compensation and say-on-pay
Advisory vote proposed to approve the compensation of named executive officers.
Shareholders to vote on the frequency of future say-on-pay votes, with a one-year interval recommended.
Latest events from Neurogene
- NGN-401 shows durable, multidomain benefits in Rett syndrome, with pivotal trial and launch prep underway.NGNE
Corporate presentation12 May 2026 - NGN-401 Embolden trial dosing nears completion; strong cash runway and interim data expected mid-2026.NGNE
Q1 202612 May 2026 - NGN-401 shows sustained, multi-domain gains in Rett syndrome with high responder rates and robust safety.NGNE
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Board recommends approval of all proposals, with detailed governance and compensation disclosures.NGNE
Proxy filing16 Apr 2026 - NGN-401 shows durable, multidomain benefits in Rett syndrome, advancing toward commercialization.NGNE
Corporate presentation24 Mar 2026 - NGN-401 advances with full trial enrollment, FDA Breakthrough status, and strong cash runway.NGNE
Q4 202524 Mar 2026 - Pivotal Rett syndrome gene therapy trial shows strong efficacy, safety, and regulatory momentum.NGNE
Stifel 2026 Virtual CNS Forum18 Mar 2026 - Durable functional gains in Rett syndrome drive NGN-401's pivotal trial and commercial plans.NGNE
Leerink Global Healthcare Conference 20269 Mar 2026 - Pivotal study for NGN-401 in Rett syndrome targets Q2 2026 completion, with strong early efficacy.NGNE
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026